Analyst Ratings For Clovis Oncology (NASDAQ:CLVS)
Today, Credit Suisse Group reiterated its Outperform rating on Clovis Oncology (NASDAQ:CLVS) with a price target of $86.00.
Some recent analyst ratings include
- 1/18/2018-Credit Suisse Group Reiterated Rating of Outperform.
- 1/11/2018-JPMorgan Chase & Co. Reiterated Rating of Buy.
- 12/20/2017-Oppenheimer Reiterated Rating of Hold.
- 11/15/2017-Leerink Swann Reiterated Rating of Outperform.
- 11/3/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 10/23/2017-Barclays initiated coverage with a Overweight rating.
- On 1/16/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $59.16 per share and the total transaction amounting to $177,480.00.
- On 1/8/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $64.97 per share and the total transaction amounting to $292,365.00.
- On 12/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $64.16 per share and the total transaction amounting to $192,480.00.
- On 12/8/2017 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.00 per share and the total transaction amounting to $270,000.00.
- On 11/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $63.70 per share and the total transaction amounting to $191,100.00.
- On 10/16/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $84.54 per share and the total transaction amounting to $253,620.00.
- On 9/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $69.50 per share and the total transaction amounting to $208,500.00.
Recent Trading Activity for Clovis Oncology (NASDAQ:CLVS)
Shares of Clovis Oncology closed the previous trading session at with 53.90999984741211 shares trading hands.